New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
08:16 EDTDEPO, MNKMallinckrodt receives patent from U.S. PTO
Mallinckrodt (MNK) announced that on July 29 the U.S. Patent and Trademark Office granted the company a new patent related to MNK-155. The patent, U.S. Patent Number 8,790,694 contains composition claims directed to unique design, formulation, pharmacokinetic, and release characteristics of MNK-155 and conveys the same period of exclusivity as did the patent granted in 2013 for the companyís product XARTEMIS XR Extended-Release Tablets. MNK-155 is Mallinckrodtís investigational extended-release oral formulation of hydrocodone and acetaminophen studied for the management of moderate to moderately severe acute pain where the use of an opioid analgesic is appropriate. The release profile of MNK-155 combines Mallinckrodt-proprietary technology and Depomedís (DEPO) advanced Acuform drug delivery technology.
News For MNK;DEPO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2015
15:32 EDTMNKViking Global reports 4.9% passive stake in Mallinckrodt
Subscribe for More Information
August 21, 2015
13:04 EDTDEPODepomed to file revocation statement with SEC
Subscribe for More Information
August 19, 2015
17:40 EDTDEPODepomed sends letter to Horizon Pharma CEO
Subscribe for More Information
17:38 EDTDEPODepomed board unanimously rejects revised proposal from Horizon Pharma
Subscribe for More Information
17:36 EDTDEPODepomed board unanimously rejects revised proposal from Horizon Pharma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use